Bernstein Liebhard LLP, a New York law firm nationally recognized for its consumer protection and mass tort practices, reports that Pfizer is conducting a review of  Zithromax adverse effects in response to a study concerning Zithromax heart problems.  Pfizer manufacturers the widely prescribed antibiotic – also known as the Z-Pak.  According to one of the company’s websites directed at healthcare professionals:

  • As of May 21, 2012, a computerized search of the medical literature identified several articles that discuss reports of cardiovascular events with azithromycin;
  • Multiple case reports reveal that individuals have experienced palpitations, tachycardia, and prolonged QT interval while taking Zithromax; and
  • Pfizer post marketing surveillance reveals that the company has “received spontaneous reports of cardiovascular adverse events since the market introduction of Zithromax.”

Although the company maintains that “a causal relationship between azithromycin and these cases has not been established,” the lawyers at Bernstein Liebhard LLP are currently investigating claims on behalf of individuals who experienced Zithromax adverse effects.  The firm is currently providing free and confidential case evaluations to those who have allegedly suffered from Zithromax heart problems.

Pfizer Reviewing Earlier Studies On Zithromax Heart Problems

In conducting its review, Pfizer identified reports of Zithromax heart problems described in several published studies.  Existing medical literature suggests that certain individuals are at an increased risk for experiencing Zithromax adverse effects, including sudden death in patients suffering from cardiovascular disease.  Pfizer identified prolonged cardiac repolarization, QT interval – which increases the risk of developing cardiac arrhythmia – and torsades de pointes as potential Zithromax adverse effects.  The company advises medical professionals that it would be prudent to avoid using the drug in certain patient populations and notes that elderly patients may be more susceptible to certain of these Zithromax side effects.

The study that sparked the Pfizer investigation, published in The New England Journal of Medicine on May 17, 2012, found that patients taking azithromycin faced a significant increased risk of sudden death from cardiac events, especially if they already have a cardiovascular condition.  The U.S. Food and Drug Administration (“FDA”) announced that same day that it would launch its own investigation into Zithromax adverse events and communicate its findings upon completion.  The FDA revised the Warnings and Precautions section of the Zithromax drug label (azithromycin extended release for oral suspension) in March 2012 to include new information regarding the risk for QT interval prolongation.

Those who have suffered damages as a result of taking Zithromax may be entitled to compensation for medical expenses, pain and suffering, lost wages and other injuries.  To learn more about Zithromax lawsuits, watch this Zithromax side effects video or visit our website,

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products.  The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past nine consecutive years.  Only two firms in the country have been selected for the Hot List nine years in a row.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP.  The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.  The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Published June 26, 2012 by